Kelly N, Clee S, Nakielna B
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
Clin Diagn Lab Immunol. 1995 Jul;2(4):499-502. doi: 10.1128/cdli.2.4.499-502.1995.
Eighty sputum samples from 37 cystic fibrosis patients were assayed for tumor necrosis factor alpha (TNF-alpha) in the L929 bioactivity assay. In addition, the presence of TNF-alpha-specific mRNA in the sputum was determined by using TNF-alpha-specific DNA probes in a PCR amplification step after reverse transcription of the mRNA to cDNA. Bioactive TNF-alpha was detected in 69 (86%) of the 80 sputum samples tested and, on at least one occasion, in 35 (95%) of the 37 cystic fibrosis patients sampled. The highest levels of TNF-alpha were observed in sputa obtained from patients presenting with an exacerbation of their disease.
采用L929生物活性分析法对37例囊性纤维化患者的80份痰液样本进行了肿瘤坏死因子α(TNF-α)检测。此外,在将mRNA逆转录为cDNA后的PCR扩增步骤中,使用TNF-α特异性DNA探针来测定痰液中TNF-α特异性mRNA的存在情况。在所检测的80份痰液样本中,有69份(86%)检测到生物活性TNF-α,在至少一次检测中,37例采样的囊性纤维化患者中有35例(95%)检测到生物活性TNF-α。在疾病加重的患者痰液中观察到最高水平的TNF-α。